NewGenIvf Group Limited (NIVF)

NewGenIvf Group Limited (NIVF) Healthcare & Pipeline Overview

NewGenIVF Group Ltd., headquartered in Bangkok, Thailand, operates as an assisted reproductive services provider, offering in-vitro fertilization, egg donation, and surrogacy services. With a P/E ratio of 0.2 and a high profit margin of 338.2%, the company focuses on fulfilling the dreams of building families in the medical care facilities sector.

What Is the Investment Thesis for NIVF?

NewGenIVF Group Ltd. presents a focused investment opportunity within the assisted reproductive services sector. The company's high profit margin of 338.2% suggests efficient operations, although the gross margin of 23.7% indicates potential areas for improvement in cost management. With a low Beta of 0.03, the stock exhibits minimal volatility relative to the market. Key value drivers include the growing demand for fertility treatments and the company's comprehensive service offerings, encompassing IVF, egg donation, and surrogacy. Growth catalysts include expanding the company's geographic reach and developing strategic partnerships. Potential risks include regulatory changes in the healthcare sector and competition from other fertility clinics. The company's P/E ratio of 0.2 may indicate undervaluation, warranting further investigation into its financial health and growth prospects.

Based on FMP financials and quantitative analysis

NIVF Key Highlights

• Profit Margin of 338.2% indicates high profitability, potentially driven by efficient cost management or premium pricing strategies.
• Gross Margin of 23.7% suggests room for improvement in cost of goods sold or pricing strategies to enhance profitability.
• P/E Ratio of 0.2 may indicate undervaluation relative to earnings, potentially offering an attractive entry point for investors.
• Beta of 0.03 suggests low volatility compared to the broader market, making it a potentially stable investment.
• No Dividend Yield reflects a strategy of reinvesting earnings for growth, which may appeal to investors seeking capital appreciation.

Who Are NIVF's Competitors?

NIVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NIVF's Key Strengths?

• High profit margin of 338.2%.
• Comprehensive range of assisted reproductive services.
• Experienced team of fertility specialists.
• Location in Bangkok, a popular destination for medical tourism.

What Are NIVF's Weaknesses?

• Relatively small size with 76 employees.
• Limited geographic presence, primarily in Bangkok.
• Gross margin of 23.7% could be improved.
• No dividend yield, which may deter some investors.

What Could Drive NIVF Stock Higher?

• Expansion into new geographic markets, particularly in regions with growing demand for fertility treatments.
• Strategic partnerships with hospitals, clinics, and other healthcare providers to expand reach and referral network.
• Implementation of advanced reproductive technologies, such as preimplantation genetic testing (PGT) and time-lapse imaging, to improve treatment outcomes (within 1-2 years).
• Diversification of service offerings to include related areas such as genetic counseling and wellness programs.

What Are the Key Risks for NIVF?

• Financial-distress signal — its Altman Z-Score of 1.72 sits in the distress zone (elevated bankruptcy risk).
• Increased competition from other fertility clinics and ART providers.
• Regulatory changes in the healthcare sector that could impact the company's operations.
• Economic downturns that could reduce demand for fertility treatments.
• Ethical and social concerns surrounding assisted reproductive technologies.
• Dependence on a relatively small team of 76 employees.

What Are the Growth Opportunities for NIVF?

• Geographic Expansion: Expanding operations into new geographic markets, particularly in regions with growing demand for fertility treatments, represents a significant growth opportunity. The global fertility services market is projected to reach $36 billion by 2026, offering ample room for expansion. Timeline: Within the next 3-5 years, NewGenIVF could establish new clinics or partnerships in key markets, leveraging its expertise and service offerings. Competitive Advantage: By focusing on underserved markets and offering specialized treatments, NewGenIVF can differentiate itself from competitors and capture market share.
• Strategic Partnerships: Forming strategic partnerships with hospitals, clinics, and other healthcare providers can expand NewGenIVF's reach and referral network. Collaborating with research institutions and universities can also enhance its technological capabilities and service offerings. Timeline: Over the next 2-3 years, NewGenIVF could forge partnerships with key players in the healthcare ecosystem, creating synergies and expanding its market presence. Competitive Advantage: By leveraging the resources and expertise of its partners, NewGenIVF can offer a more comprehensive and integrated suite of services, attracting a wider range of clients.
• Technological Advancements: Investing in advanced reproductive technologies, such as preimplantation genetic testing (PGT), time-lapse imaging, and artificial intelligence (AI)-assisted embryo selection, can improve treatment outcomes and attract clients seeking the latest innovations. The market for reproductive technologies is growing rapidly, driven by the increasing demand for fertility treatments and the desire for higher success rates. Timeline: Within the next 1-2 years, NewGenIVF could implement new technologies in its clinics, enhancing its service offerings and improving patient outcomes. Competitive Advantage: By staying at the forefront of technological advancements, NewGenIVF can differentiate itself from competitors and attract clients seeking the most advanced fertility treatments.
• Service Diversification: Diversifying its service offerings to include related areas such as genetic counseling, reproductive endocrinology, and wellness programs can enhance NewGenIVF's value proposition and attract a broader range of clients. The market for complementary services is growing, as individuals and couples seek holistic support throughout their fertility journey. Timeline: Over the next 2-3 years, NewGenIVF could expand its service offerings to include complementary services, creating a more comprehensive and integrated patient experience. Competitive Advantage: By offering a one-stop-shop for fertility-related services, NewGenIVF can attract clients seeking convenience and comprehensive care.
• Marketing and Branding: Enhancing its marketing and branding efforts to increase awareness and attract new clients represents a significant growth opportunity. The fertility services market is competitive, and effective marketing is essential for attracting clients and building brand recognition. Timeline: Within the next 6-12 months, NewGenIVF could launch new marketing campaigns, revamp its website, and increase its presence on social media, enhancing its brand visibility and attracting new clients. Competitive Advantage: By developing a strong brand identity and effectively communicating its value proposition, NewGenIVF can differentiate itself from competitors and attract clients seeking high-quality fertility treatments.

What Opportunities Does NIVF Have?

• Expanding into new geographic markets.
• Forming strategic partnerships with hospitals and clinics.
• Investing in advanced reproductive technologies.
• Diversifying service offerings to include related areas such as genetic counseling.

What Threats Does NIVF Face?

• Competition from other fertility clinics and ART providers.
• Regulatory changes in the healthcare sector.
• Economic downturns that could reduce demand for fertility treatments.
• Ethical and social concerns surrounding assisted reproductive technologies.

What Are NIVF's Competitive Advantages?

• Specialized expertise in assisted reproductive technologies.
• Established reputation and brand recognition in the Bangkok area.
• Comprehensive service offerings, including IVF, egg donation, and surrogacy.
• Focus on personalized care and patient support.

What Does NIVF Do?

NewGenIVF Group Ltd. is an assisted reproductive services provider dedicated to offering fertility treatments to individuals and couples seeking to build families. Headquartered in Bangkok, Thailand, the company specializes in a range of services, including in-vitro fertilization (IVF), egg donation, surrogacy, and ancillary caring services. NewGenIVF aims to provide comprehensive support throughout the fertility journey, addressing the diverse needs of its clients. The company's core offering is in-vitro fertilization treatment, encompassing both traditional IVF methods and egg donation programs. These services are designed to assist individuals and couples facing challenges with natural conception. Additionally, NewGenIVF provides surrogacy services, offering a pathway to parenthood for those who are unable to carry a pregnancy themselves. Ancillary caring services complement the core treatments, ensuring that clients receive holistic support throughout the process. With a focus on personalized care and advanced reproductive technologies, NewGenIVF Group Ltd. strives to be a leading provider in the assisted reproductive services market, helping individuals and couples achieve their dreams of starting a family.

What Products and Services Does NIVF Offer?

• Provides in-vitro fertilization (IVF) treatments to individuals and couples.
• Offers egg donation services for those who require donor eggs.
• Facilitates surrogacy arrangements for individuals or couples unable to carry a pregnancy.
• Offers ancillary caring services to support clients throughout the fertility treatment process.
• Aims to fulfill the dreams of building families through assisted reproductive technologies.
• Operates fertility clinics in Bangkok, Thailand.

How Does NIVF Make Money?

• Generates revenue by providing IVF treatments, egg donation, and surrogacy services.
• Charges fees for ancillary caring services, such as counseling and support programs.
• May offer package deals or financing options to make treatments more accessible.
• Focuses on providing personalized care and advanced reproductive technologies to attract clients.

What Industry Does NIVF Operate In?

NewGenIVF Group Ltd. operates within the assisted reproductive technology (ART) industry, a segment of the healthcare sector experiencing steady growth due to increasing infertility rates, advancements in medical technology, and changing social norms. The market is competitive, with numerous fertility clinics and ART providers vying for market share. Key trends include the rising demand for IVF, egg donation, and surrogacy services, as well as the increasing adoption of advanced technologies such as preimplantation genetic testing (PGT) and time-lapse imaging. NewGenIVF's focus on comprehensive fertility treatments positions it to capitalize on these trends, although it faces competition from established players and emerging clinics.

Who Are NIVF's Key Customers?

• Individuals and couples struggling with infertility.
• Individuals or couples who are unable to conceive naturally.
• Same-sex couples seeking to have children.
• Individuals or couples who require egg donation or surrogacy services.

F-Score 5/9Financial Health

NewGenIvf Group Limited's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.72 places it in the distress zone, a signal of elevated financial risk.

ROE 33%Key Financial Metrics

Return on equity for NewGenIvf Group Limited stands at 32.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 28.0%, showing how much profit it generates from its asset base. NIVF trades at a trailing price-to-earnings ratio of 0.18, below the Healthcare sector average of ~23x. A current ratio of 3.12 indicates the company holds enough short-term assets to cover its near-term obligations.

NewGenIvf Group Limited (NIVF) Valuation Context

Valued at 280K, NIVF is classified as a micro-cap stock. Relative to its peer group, NIVF's quantitative score of 43/100 is below the peer average of 60/100.

FY2026 estForward Outlook

Wall Street analysts project NewGenIvf Group Limited revenue of about $65.1M for fiscal 2026, with EPS near $4.74.

NIVF Financials

NIVF Latest News

NIVF Analyst Consensus

NIVF MoonshotScore

What Investors Ask About NewGenIvf Group Limited (NIVF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources